30 results about "Hyperammonemia" patented technology

Disclosed are compositions containing exosomes loaded with arginase or arginase chimeras for treating hyperammonemia due to arginase deficiency, and methods for treating hyperammonemia by administering compositions containing exosomes loaded with arginase or arginase chimeras.

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of hyperammonemia-related diseases (e.g., urea cycle disorders and hepatic encephalopathy).

To provide a composition for preventing, ameliorating or treating a disease caused by protein nitration comprising a peptide with terminal tyrosine as an effective component.SOLUTION: A peptide with terminal tyrosine has an excellent effect of inhibiting protein nitration and also an excellent effect of preventing, ameliorating or treating disease symptoms in chronic immobilization stress-induced depression / cognitive impairment model, Alzheimer's disease model, epileptic seizure model, stroke model, type 2 diabetes model, acute renal failure model, or hyperammonemia model.SELECTED DRAWING: None

To provide a composition for preventing, ameliorating, or treating a disease caused by nitration of tyrosine in proteins comprising tyrosine as an effective component.SOLUTION: Tyrosine as an effective component of the present invention not only can enhance the activity of GS having reduced activity and but also has an effect of restoring the amount (i.e., ratio) of glutamine and glutamic acid in brain and the amount of ammonia to normal level, an effect of enhancing the insulin sensitivity in a model of type 2 diabetes, an effect of suppressing the excitotoxicity and oxidative stress in a model of epileptic seizure, an effect of reducing cerebral infarction and enhancing the activity of GS in a model of brain stroke, an effect of eliminating the nitration of tyrosine using human recombinant MnSOD, and an effect for acute renal failure and hyperammonemia. Therefore, the tyrosine as an effective component of the present invention can be efficiently used as a functional health food composition for preventing or ameliorating a disease caused by nitration of tyrosine in proteins or a pharmaceutical composition for preventing or treating a disease caused by nitration of tyrosine in proteins.SELECTED DRAWING: Figure 1

The invention provides an application of a component A as or used for preparing an SIRT5 inducer, the component A at least comprises one or more than two of ergothioneine, ectoine and hyaluronic acid or salt thereof, and the component A can be used for the SIRT5 inducer or used for preparing an SIRT5 expression inducer, so that cell aging can be inhibited, and the SIRT5 inducer can be used for preparing an SIRT5 expression inducer. The traditional Chinese medicine composition is used for improving natural skin aging, cardiac hypertrophy and / or hyperammonemia.

The invention belongs to the technical field of biochemistry, and particularly provides a carbonic anhydrase binding ligand which comprises at least one of euphorbia alcohol type diterpene and olivone type diterpene. The carbonic anhydrase binding ligand has the effects of resisting tumors, viruses, fungi and inflammation, treating edema, glaucoma, senile dementia, hyperammonemia and the like. An enzymology experiment shows that the compound is a carbonic anhydrase agonist and also has industrial applications of capturing and fixing carbon dioxide, accelerating mineralization of biological tissues and corals and the like. The invention also provides a preparation method of the carbonic anhydrase binding ligand, which takes euphorbia kansui as a raw material, is simple to prepare and provides a new way for application of euphorbia kansui.

Disclosed are compositions containing exosomes loaded with arginase or arginase chimeras for treating hyperammonemia due to arginase deficiency, and methods for treating hyperammonemia by administering compositions containing exosomes loaded with arginase or arginase chimeras.

Methods, formulations, and applications of treating and preventing hyperammonemia by reducing ammonia levels are provided, which also have implications for reducing hemodialysis.

The peptide with tyrosine at the terminal has an excellent effect of inhibiting protein nitration; the composition has an excellent effect of preventing, improving or treating disease symptoms in a chronic body-bound stress depression / cognitive disorder inducing model, an Alzheimer disease dementia model, an epileptic seizure model, a cerebral apoplexy model, a type 2 diabetes mellitus model, an acute renal failure model or a hyperammonemia model.

Microorganisms for lowering blood ammonia level and composition for protecting neuronal cells containing the same, particularly relates to microbes or a symbiotic pair that has a neuroprotective function by lowering blood ammonia levels or reducing ammonia levels in the body and composition for protecting neuronal cells comprising the microbes. The microorganisms having a neuroprotective function by lowering the blood ammonia level can be selected from the group that include, but not limited to, a Lactobacillus sp. strain and a Streptococcus sp. strain. The ammonia removal strains and the composition have a neuroprotective effect by their excellent ability to remove neurotoxic ammonia, and thus can be widely used as a preventive or therapeutic agent for hyperammonemia and neurological diseases caused thereby.

The present invention relates to a composition for preventing, ameliorating or treating diseases caused by nitration of tyrosine in a protein, comprising tyrosine as an active ingredient. The tyrosine as an active ingredient of the present invention not only enhances reduced GS activity, but also can restore the content (proportion) of glutamine and glutamic acid in the brain and the amount of ammonia to a normal state. The composition has an insulin sensitivity enhancing effect in a type 2 diabetes mellitus model, an excitatory toxicity and oxidative stress inhibiting effect in an epileptic seizure model, a cerebral infarction reducing and GS activity enhancing effect in a stroke model, a tyrosine denitration effect using human recombinant MnSOD, an acute renal failure effect, and a hyperammonemia effect. Therefore, the compound can be effectively used as a health-care functional food composition for preventing or alleviating diseases caused by tyrosine nitrification in proteins or as a pharmaceutical composition for preventing or treating diseases caused by tyrosine nitrification in proteins.

The peptide having a tyrosine residue at the end of the present invention has an excellent effect of inhibiting protein nitration and has an excellent effect of preventing, improving or treating disease symptoms in a chronic physical restraint stress depression / cognitive impairment induced model, an Alzheimer's disease dementia model, an epileptic seizure model, a stroke model, a type 2 diabetes model, an acute renal failure model or a hyperammonemia model.

The present disclosure provides the use of a liposome suspension comprising transmembrane pH gradient liposomes in the treatment of acute hyperamminemia crisis (HAC) associated with innate metabolic error (IEM) in a subject, wherein the treatment comprises intraperitoneal administration of the liposome suspension to the subject and removal of a dialysate containing ammonia-loaded liposomes from the subject.

A method for ameliorating a disease caused by nitration of tyrosine in protein includes administering a composition comprising tyrosine or a salt thereof to a subject in need thereof. Tyrosine as effective component of the present invention not only can enhance the activity of glutamine synthetase having reduced activity and but also has an effect of restoring the amount (i.e., ratio) of glutamine and glutamic acid in brain and the amount of ammonia to normal level, an effect of enhancing the insulin sensitivity in a model of type 2 diabetes, an effect of suppressing the excitotoxicity and oxidative stress in a model of epileptic seizure, an effect of reducing cerebral infarction and enhancing the activity of GS in a model of brain stroke, an effect of eliminating the nitration of tyrosine using human recombinant MnSOD, and an effect for acute renal failure and hyperammonemia.

The pharmaceutical compounds have anti-inflammatory activity. A pharmaceutical composition may include a therapeutically effective amount of a compound and a pharmaceutically acceptable carrier. A method of treating hemopigmentation, hyperammonemia, or a disease associated with chronic inflammation or cancer comprises administering a pharmaceutical composition to an individual in need thereof. In another aspect, a method of inhibiting metal oxide formation or reducing metal reactivity includes contacting a metal with an effective amount of a compound.

The present disclosure provides a use of a liposomal suspension comprising transmembrane pH-gradient liposomes, for the treatment of an acute hyperammonemia episode (HAC) associated with inborn errors of metabolism (IEM) in a subject, wherein the treatment comprises intraperitoneally administering the liposomal suspension to the subject and removing a dialysate containing ammonia-loaded liposomes from the subject.

To provide a pharmaceutical composition for treating or preventing hyperammonemia and hepatic encephalopathy.SOLUTION: A pharmaceutical composition for treating or preventing hyperammonemia contains rifaximin and conjugated bile acid.SELECTED DRAWING: None

The present disclosure provides implantable engineered tissue constructs having hepatocytes and stromal cells for the treatment of hyperammonemia.

The peptide with tyrosine at the terminal has an excellent effect of inhibiting protein nitration; the composition has an excellent effect of preventing, improving or treating disease symptoms in a chronic body-bound stress depression / cognitive disorder inducing model, an Alzheimer disease dementia model, an epileptic seizure model, a cerebral apoplexy model, a type 2 diabetes mellitus model, an acute renal failure model or a hyperammonemia model.

The present invention relates to the use of glutamine synthetase as a protein therapy (such as enzyme replacement protein therapy) for the treatment of hyperammonemia. In particular the invention relates to the systemic administration of glutamine synthetase. The glutamine synthetase may be provided in conjugated or fusion form, to increase its half-life in the circulation. Also provided is a pharmaceutical composition comprising glutamine synthetase. The invention also relates to the uses, methods, and compositions involving a combination of the glutamine synthetase protein and an ammonia lowering agent, such as a nitrogen scavenger.

The invention relates to an application of a herba epimedii extract in preparation of a medicine for treating and / or preventing hyperammoemia related diseases, and belongs to the technical field of biological medicines. The invention provides an application of a herba epimedii extract in preparation of a medicine for treating and / or preventing hyperamminemia related diseases. In the research, the applicant discovers that the total flavonoids of herba epimedii can obviously reduce the blood ammonia and brain ammonia level of acute hepatic failure mice induced by lipopolysaccharide and D-galactosamine, and prompts that the total flavonoids of herba epimedii can obviously reduce the blood ammonia and brain ammonia level, and can be used for preparing medicines for treating and / or preventing diseases related to hyperammoemia.

The invention discloses a composite hydrogel system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method comprises the following steps: jointly encapsulating chlorella and sodium phenylbutyrate in semi-interpenetrating network hydrogel formed by cross-linking carboxymethyl chitosan and sodium alginate through genipin, so as to prepare a composite hydrogel system with an oral administration function. The hydrogel system has good colon targeted release characteristics and pH responsiveness, can prolong the retention time of drugs in gastrointestinal tracts, protects chlorella from being damaged by gastric acid and enzymolysis, realizes dual-channel removal of ammonia, and effectively inhibits growth of colorectal cancer. The system can regulate intestinal microbiota, enrich beneficial bacteria such as ackermann muciniphile and improve the intestinal microenvironment. The hydrogel system is good in biocompatibility, high in long-term oral administration safety, wide in raw material source, low in cost, simple in preparation process and easy for large-scale production, and has an important clinical application prospect in the field of combined treatment of hyperammonemia and colorectal cancer.

The present disclosure provides use of a liposomal suspension comprising transmembrane pH gradient liposomes for the treatment of acute hyperammonemic episodes (HAC) associated with an inborn error of metabolism (IEM) in a subject, the treatment comprising intraperitoneally administering the liposomal suspension to the subject and removing dialysate containing ammoniated liposomes from the subject.

The invention relates to an application of a jasminum grandiflorum extract in preparation of a medicine for treating and / or preventing hepatic encephalopathy, belonging to the technical field of biological medicines. The invention provides an application of oleuropein in preparation of a medicine for treating and / or preventing hyperamminemia related diseases. The invention provides an application of a jasminum grandiflorum extract in preparation of a medicine for treating and / or preventing diseases related to hyperamniemia and further provides a medicine composition for treating and / or preventing the diseases related to the hyperamniemia, and the medicine composition comprises oleuropein or the jasminum grandiflorum extract and pharmaceutically acceptable auxiliary materials. Experiments prove that the jasminum grandiflorum extract or oleuropein can remarkably reduce the blood ammonia and brain ammonia levels of mice with acute liver injury and relieve pathological states such as astrocyte swelling caused by hyperammoemia, has the effects of reducing blood ammonia and brain ammonia, and can be used for treating hyperammoemia.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a mangnolia officinalis extract or a structural analogue thereof in preparation of a medicament for treating hyperinsulinemia / hyperamminemia syndrome. The invention provides a new application of a mangnolia officinalis extract represented by honokiol. Research shows that the mangnolia officinalis extract or the structural analogue thereof can well inhibit the activity of glutamate dehydrogenase (GDH), including wild type GDH and GDH capable of causing acquisition function mutation of the hyperinsulinemia / hyperamminemia (HI / HA) syndrome, so that the effect of the mangnolia officinalis extract or the structural analogue thereof as a GDH inhibitor in treatment of the HI / HA syndrome is expanded, and the application of the mangnolia officinalis extract or the structural analogue thereof in treatment of the HI / HA syndrome is promoted. Effective attempts are made for solving the problem that existing medicines for treating the rare HI / HA syndrome are rare, the current situation of treating the HI / HA syndrome can be remarkably improved, the situation of lack of targeted medicines is broken through, the life quality of patients is improved, and the family and social burden of the patients is greatly relieved.

The present invention relates to the use of glutamine synthetase as a protein therapy (such as enzyme replacement protein therapy) for the treatment of hyperammonemia. In particular the invention relates to the systemic administration of glutamine synthetase. The glutamine synthetase may be provided in conjugated or fusion form, to increase its half-life in the circulation. Also provided is a pharmaceutical composition comprising glutamine synthetase. The invention also relates to the uses, methods and compositions involving a combination of the glutamine synthetase protein and an ammonia lowering agent, such as a nitrogen scavenger.

The invention belongs to the technical field of biological medicines, and relates to application of a histone deacetylase inhibitor HDACi in preparation of a medicine for preventing and / or treating hyperammonemia-induced encephalopathy. According to the invention, a histone deacetylase inhibitor HDACi is used as a new medicine, the HDACi can enter a central nervous system, and the GS is triggered to be degraded through a proteasome mediated by CRBN E3 ubiquitin ligase by improving the acetylation level of a key enzyme, namely glutamine synthetase (GS), of astrocytes, so that the GS protein abundance is reversibly reduced, and the GS protein abundance is reduced. The application has the advantages that pathological accumulation of toxic metabolite glutamine can be reduced from the source, cerebral edema, autophagy-lysosomal dysfunction, neuroinflammation and neuron injury caused by the pathological accumulation can be synchronously improved, severe neurotoxicity such as persistent enzyme inhibition and acute epilepsy caused by irreversible inhibitors such as MSO can be avoided, clinical transformation risks can be obviously reduced, and the safety is high.

The application relates to the field of biological medicine, in particular to application of sodium tiglate in preparation of products for promoting liver regeneration and reducing blood ammonia; it is found and disclosed for the first time in the application that sodium tiglate can be applied to preparation of liver regeneration or liver function recovery products, liver cell proliferation capacity of residual liver after partial hepatectomy can be improved by using sodium tiglate, blood ammonia level after liver surgery is controlled, nitrogen metabolism disorder is improved by promoting conversion of blood ammonia into urea, and liver cell regeneration capacity is improved; the application of sodium tiglate provides a new treatment strategy with clear action mechanism and wide development prospect for treatment of insufficient liver regeneration after partial hepatectomy and hyperammonemia.